Cancer cell associated glycans as targets for immunotherapy

OncoImmunology

Volumn 5, Issue 1, 2016, Pages

  Vankemmelbeke, Mireille ^a   Chua, Jia Xin ^a   Durrant, Lindy G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

ADC; Glycomics; Lewis glycan; Programmed cell death; Therapeutic antibody

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCAN SPECIFIC ANTIBODY; KW2871; MONOCLONAL ANTIBODY; RACOTUMOMAB; TOSITUMOMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CELL LINE; CANCER IMMUNOTHERAPY; CELL KILLING; DRUG CROSS REACTIVITY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84954418340     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1061177     Document Type: Article

References (10)

1. Dalziel M, Crispin M, Scanlan CN, Zitzmann N, Dwek RA. Emerging principles for the therapeutic exploitation of glycosylation. Science 2014; 343:1235681; PMID:24385630; http://dx. doi. org/ 10. 1126/science. 1235681
2. Drake RR. Glycosylation and cancer: moving glycomics to the forefront. Adv Cancer Res 2015; 126:1-10; PMID:25727144; http://dx. doi. org/10. 1016/bs. acr. 2014. 12. 002
3. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005; 5:526-42; PMID:16069816; http://dx. doi. org/ 10. 1038/nrc1649
4. Hakomori SI, Cummings RD. Glycosylation effects on cancer development. Glycoconj J 2012; 29:565-6; PMID:22996057; http://dx. doi. org/10. 1007/s10719-012-9448-4
5. Rabu C, McIntosh R, Jurasova Z, Durrant L. Glycans as targets for therapeutic antitumor antibodies. Future Oncol 2012; 8:943-60; PMID:22894669; http://dx. doi. org/10. 2217/fon. 12. 88
6. Chua JX, Vankemmelbeke M, McIntosh RS, Clarke PA, Moss R, Parsons T, Spendlove I, Zaitoun AM, Madhusudan S, Durrant LG. Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity. Clin Cancer Res 2015; 21(13):2963-74; http://dx. doi. org/10. 1158/1078-0432. CCR-14-3030
7. Stanley P, Cummings RD. Structures Common to Different Glycans. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, eds. Essentials of Glycobiology: Cold Spring Harbor, NY, 2009.
8. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actindependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011; 117:4519-29; PMID:21378274; http://dx. doi. org/10. 1182/blood-2010-07-296913
9. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860-75; PMID:23151605; http://dx. doi. org/ 10. 1038/nrc3380
10. Kepp O, Senovilla L, Kroemer G. Immunogenic cell death inducers as anticancer agents. Oncotarget 2014; 5:5190-1; PMID:25114034